CDKN2A/B Deletions Are Associated With Inferior Outcomes With First-Line Immune Checkpoint Inhibitor-Based Therapy in Advanced Non-small Cell Lung Carcinoma

JTO Clinical and Research Reports · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles